UnknownPhase 3

Low Dose Heparin Factorial Trial

Pakistan800 participantsStarted 2022-05-09

Plain-language summary

An open label 2x2 factorial randomized trial is planned to determine the difference in mean hemostasis time between low dose heparin (LD) i.e between 2000-3000 IU and standard dose heparin (SD) i.e. 5000 IU with or without catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc. S Korea) used in conjunction with TRB (InnoSEAL+TRB \[I+TRB\]) among patients who are undergoing left heart cath at Tabba Heart Institute. Secondary objectives include testing the difference in radial artery occlusion (RAO), and hematoma (III, IV grade) and composite outcome (RAO+hematoma).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hemodynamically stable adult patients of both genders, who will undergo transradial coronary angiogram (CAG) using 6 F sheath will be included. Exclusion Criteria: * Patients who had STEMI, are on anticoagulants after procedure or on an ongoing anticoagulation therapy, have ipsilateral arteriovenous fistula, RAO at baseline, Barbeau's class D will be excluded.

What they're measuring

Compression time

Timeframe: 45 minutes

Trial details

NCT IDNCT05591872

SponsorTabba Heart Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-30

Contact for this trial

Sana Sheikh, M.Sc

+92-21-36811841 sana.sheikh@tabbaheart.org

View on ClinicalTrials.gov More Radial Artery Occlusion trials